Toll Free: 1-888-928-9744
Published: Jun, 2014 | Pages:
36 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Signature Therapeutics, Inc - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Signature Therapeutics, Inc - Product Pipeline Review - 2014', provides an overview of the Signature Therapeutics, Inc's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Signature Therapeutics, Inc's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Signature Therapeutics, Inc including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Signature Therapeutics, Inc's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Signature Therapeutics, Inc's pipeline products Reasons to buy - Evaluate Signature Therapeutics, Inc's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Signature Therapeutics, Inc in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Signature Therapeutics, Inc's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Signature Therapeutics, Inc and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Signature Therapeutics, Inc - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Signature Therapeutics, Inc and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Signature Therapeutics, Inc Snapshot 5 Signature Therapeutics, Inc Overview 5 Key Information 5 Key Facts 5 Signature Therapeutics, Inc - Research and Development Overview 6 Key Therapeutic Areas 6 Signature Therapeutics, Inc - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Signature Therapeutics, Inc - Pipeline Products Glance 11 Signature Therapeutics, Inc - Clinical Stage Pipeline Products 11 Phase I Products/Combination Treatment Modalities 11 Signature Therapeutics, Inc - Early Stage Pipeline Products 12 Preclinical Products/Combination Treatment Modalities 12 Discovery Products/Combination Treatment Modalities 14 Signature Therapeutics, Inc - Drug Profiles 15 PF-329 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 PF-6129 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 PF-614 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 PFR-03088 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 PFR-03318 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 PFR-03321 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 PFR-06158 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 PFR-06177 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 PFR-08001 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 PFR-8026 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 PFR-03323 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 PFR-03325 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Signature Therapeutics, Inc - Pipeline Analysis 28 Signature Therapeutics, Inc - Pipeline Products by Target 28 Signature Therapeutics, Inc - Pipeline Products by Route of Administration 29 Signature Therapeutics, Inc - Pipeline Products by Molecule Type 30 Signature Therapeutics, Inc - Pipeline Products by Mechanism of Action 31 Signature Therapeutics, Inc - Recent Pipeline Updates 32 Signature Therapeutics, Inc - Dormant Projects 33 Signature Therapeutics, Inc - Locations And Subsidiaries 34 Head Office 34 Appendix 35 Methodology 35 Coverage 35 Secondary Research 35 Primary Research 35 Expert Panel Validation 35 Contact Us 36 Disclaimer 36
List of Tables Signature Therapeutics, Inc, Key Information 5 Signature Therapeutics, Inc, Key Facts 5 Signature Therapeutics, Inc - Pipeline by Indication, 2014 8 Signature Therapeutics, Inc - Pipeline by Stage of Development, 2014 9 Signature Therapeutics, Inc - Monotherapy Products in Pipeline, 2014 10 Signature Therapeutics, Inc - Phase I, 2014 11 Signature Therapeutics, Inc - Preclinical, 2014 12 Signature Therapeutics, Inc - Discovery, 2014 14 Signature Therapeutics, Inc - Pipeline by Target, 2014 28 Signature Therapeutics, Inc - Pipeline by Route of Administration, 2014 29 Signature Therapeutics, Inc - Pipeline by Molecule Type, 2014 30 Signature Therapeutics, Inc - Pipeline Products by Mechanism of Action, 2014 31 Signature Therapeutics, Inc - Recent Pipeline Updates, 2014 32 Signature Therapeutics, Inc - Dormant Developmental Projects,2014 33
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.